We are soliciting novel oral small-molecule drug candidates in the field of innate immunity for inflammatory and immune indications.
Eligible programs must have IND filings completed in both China and the US, or be currently in Phase I clinical trials. Key requirements include novel mechanisms of action, well-defined targets, strong differentiation, clear intellectual property status, and complete preclinical datasets to support rapid clinical advancement.
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
